SCHEMBL24322394

SCHEMBL24322394

Cc1c(-c2nc(N)ncc2F)sc2c1ncn2C(C)C

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCND1 P24385 10/20 0.42
CDK4 P11802 6/20 0.42
CDK6 Q00534 5/20 0.42
CDK1 P06493 2/20 0.37
CCNB1 P14635 2/20 0.37
CCNE1 P24864 2/20 0.37
CDK2 P24941 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
PIK3CA P42336 2/20 0.34
MTOR P42345 2/20 0.34
MAPK14 Q16539 1/20 0.34
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
PI4KA P42356 1/20 0.33
PI4K2B Q8TCG2 1/20 0.33
PI4K2A Q9BTU6 1/20 0.33
PI4KB Q9UBF8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29514922 0.86 CCND1 (0.42) CCND1CDK4CDK6CDK2SMN1; SMN2
SCHEMBL24322278 0.86 CCND1 (0.42) CCND1CDK4CDK6CDK2SMN1; SMN2
SCHEMBL29515154 0.81 CCND1 (0.61) CCND1CDK4CDK6CDK2PIK3CA
SCHEMBL24323498 0.81 CCND1 (0.61) CCND1CDK4CDK6CDK2PIK3CA
SCHEMBL24323029 0.74 SMN1; SMN2 (0.47) CCND1CDK6CDK1CCNB1CCNE1
SCHEMBL29514966 0.70 CCND1 (0.36) CCND1CDK4CDK6
SCHEMBL24322292 0.70 CCND1 (0.36) CCND1CDK4CDK6
SCHEMBL24323030 0.70 SMN1; SMN2 (0.44) CCND1CDK6CDK1CCNB1CCNE1
SCHEMBL29514974 0.69 CDK6 (0.78) CCND1CDK4CDK6CDK1CCNB1
SCHEMBL29515037 0.69 CCND1 (0.62) CCND1CDK4CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 US disclosed
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals PRELUDE THERAPEUTICS, INCORPORATED 2023-11-09 US disclosed
EP-4214213-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS Prelude Therapeutics, Incorporated (US) 2023-07-26 EP disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 US disclosed
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals PRELUDE THERAPEUTICS INCORPORATED (US) 2023-06-27 US disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 WO disclosed
WO-2022061273-A1 CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS PRELUDE THERAPEUTICS, INCORPORATED (US) 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357265-A1 CDK Inhibitors And Their Use As Pharmaceuticals CDK6, CDK1, CDK3 CCND1 46/4885CDK4 12/4885CDK6 1/4885
US-11685744-B2 CDK inhibitors and their use as pharmaceuticals CDK6, CDK1, CDK3 CCND1 46/4885CDK4 12/4885CDK6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.